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As part of ECF management, nutrition plays a vital role in determining the prognosis as a 
predicator for both morbidity and mortality. Malnutrition can occur as a preceding 
situation or complication in ECF cases caused by the underlying disease, decreased food 
intake, increased protein requirements associated with systemic inflammation, and 
increased nutrient loss associated with the amount of fistula output. Therefore, nutrition 
management can act as prevention, therapy, or even both. The purpose of nutritional 
medical therapy in ECF cases is to adequately estimate nutritional needs, maintain fluid 
and electrolyte balance, and stimulate spontaneous ECF closure whenever possible. An 
analysis of nutrition needs has to be carried out individually by considering the etiology, 
the anatomical fistula location, and the amount of output. In the following article, we will 
discuss a comprehensive step-by-step nutrition treatment, by taking into account 
nutritional routes, macronutrient and micronutrient requirements, specific nutrients, 
pharmacotherapy, and monitoring and evaluation as to produce an optimal clinical 
outcome. 
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Introduction 
 
Enterocutaneous fistula (ECF) incidence varies from 
5 to 10% according to the etiology.1 About 75% of 
ECF cases are adhered to iatrogenic causes which 
generally result from surgical complications, while 
the rest are linked to spontaneous causes such as 
inflammatory, radiation, and trauma conditions.2,3 
At the present, there is no incident data concerning 
ECF cases in Indonesia. 
It is estimated that 50-90% of ECF patients 
experience nutritional problems, including 
malnutrition, dehydration, or electrolyte disorders.4 
Sepsis, malnutrition, and fluid and electrolyte 
imbalance, referred to as "fistula triad", significantly 
increase the risk of mortality and significantly 
reduce the rate of spontaneous fistula closure.2 
Patients with ECF are at high risk of malnutrition 
due to decreased food intake, ineffective nutritional 
therapy resulting from a large number of nutrients 
that come out along with enteric secretions, and 
changed metabolism caused by the underlying 
disease.5,6  
Optimal ECF management involves a 
multidisciplinary team, consisting of surgery, 
nutrition, nursing, and pharmacy departments. 
Institutions with sufficient experience and 
appropriate ECF treatment can reduce the mortality 
rate by up to 50%.1 In terms of prognosis, it is found 
that patients experiencing no malnutrition are 15 
times greater to have spontaneous closure of 
fistulas.7,8 As cited from Davis KG et al, the rate of 
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fistula closure is also twice lower in patients who do 
not receive nutritional interventions than in those 
who receive nutritional interventions.4 Thus, it is 
crucial to comprehend a step-by-step approach of 
nutrition management in order to reduce the rates of 
both morbidity and mortality in ECF cases. 
 
Step-by-Step approach in ECF nutrition 
management 
 
In ECF nutrition management, fluid resuscitation, 
electrolyte imbalance correction, and sepsis control 
have to be conducted before nutrition is given to 
ECF patients.1 However, it is important that a 
nutrition plan has previously been well prepared for 
them. In this regard, nutrition management typically 
includes assessing patients’ nutritional status, 
selecting the nutrition routes, determining 
macronutrients, micronutrients, and specific 
nutrients, providing pharmacotherapy, and carrying 
out monitoring and evaluation. These proposed steps 
are presented in Figure 1.  
 
 
1. Assessing patients’s nutritional status 
 
Malnutrition screening has to be done at the 
beginning of the diagnosis. If malnutrition is not 
detected during the initial diagnosis, periodic 
screening then becomes necessary. To date, no 
malnutrition screening methods are validated 
explicitly for use under ECF conditions.11 Some of 
the validated screening tools that can be used easily 
are Nutritional Risk Screening (NRS) 2002, 
Malnutrition Universal Screening Tool (MUST), 
and Subjective Global Assessment (SGA).16 
Patients with ECF often experience malnutrition 
caused by the underlying disease, decreased food 
intake, increased protein requirements associated 
with systemic inflammation, and increased nutrient 
loss associated with the amount of fistula output. 
Nutritional status functions principally as a predictor 
of spontaneous fistula closure. According to de 
Aguilar-Nascimento, et al., patients with no 
malnutrition are 15 times greater to have 
spontaneous closure of fistulas (OR = 15.4 [95% CI 
= 1.1-215.5]; p = 0.04).8  
Despite being frequently measured before and 
during nutritional therapy of ECF patients, serum 
protein levels do not function as a marker for 
sensitive nutritional status. Decreased 
concentrations of serum plasma albumin, 
transferrin, retinol-binding proteins, and prealbumin 
are likely a consequence of systemic inflammation 
associated with ECF.11 Besides, albumin levels can 
be found to be extremely high in ECF patients due 
to  decreased plasma volume, especially in high-
output fistulas.17 Prealbumin, also known as 
transthyretin, is an acute negative visceral protein 
and reactant that is normally influenced by the same 
factors affecting albumin levels. Nonetheless, it is 
more recommended than albumin due to having a 
relatively short half-life of 2 days. Subsequently, 
prealbumin concentrations can become a predictor 
of recent food intake.18 This means that serum 
protein concentrations obtained before and during 
nutritional therapy can not be used as a marker of the 
nutritional status, but as an indicator of the 
prognosis.11 
 
2. Stabilizing patients through rehabilitation phase 
 
As regards with rehabilitation phase, oral nutrition is 
normally stopped (nil per os, NPO), and nutrition is 
given through total parenteral nutrition (TPN). TPN 
should be given within a short duration to reduce the 
risk of complications, especially if given through a 
central route with a target nutritional requirement of 
30-40 ml/kg of fluid, 30-40 kcal/kg of calories, and 
1.5-2 g/kg of protein. The strict control of blood 
glucose levels is needed to avoid the occurrence of 
hyperglycemia. The ratio of carbohydrates, fats, and 
proteins in TPN can be modified according to 
patients' medical histories.3 When hemodynamics 
are stable, it is advisable to immediately provide 
enteral nutrition (EN) to prevent villous atrophy, 
which is also termed as "gut feeding". Clear liquid 
diets can be given as an option during gut feeding, 
with components that provide energy, electrolytes, 
and no concentrated or carbonated sweeteners and 
leave minimal residues in the gastrointestinal tract. 
Examples of clear liquid diets include broth, coffee, 
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Nutritional routes should be selected based on 
various considerations, including the location of 
fistulas, the length of the healthy intestine for 
nutrient absorption, the signs of distal obstruction, 
and the amount of fistula output. An in-depth 
assessment of fistula characteristics (e.g., 
anatomical position and length) is required. In ECF 
cases without distal obstruction, patients with low 
output (<500 mL/day) can tolerate an oral diet. If 
oral food intake is associated with a significant 
increase in ECF output or is not tolerated by patients 
for other reasons, EN can be tried and tolerated when 
enteral access can be obtained. Relative 
contraindications to EN include insufficient 
intestinal length (75cm), intestinal discontinuity, 
intolerance of symptoms to enteral nutrition, 
increased fistula output leading to electrolyte 
disturbances at the beginning of enteral nutrition, 
and inability to maintain food access.6  
Patients’ EN tolerance and ability to achieve the 
target intake must be evaluated on a daily basis. If 
nutritional goals cannot be achieved only with EN, 
combined nutrition therapy of EN and PN can be 
initiated. High-calorie supplementary drinks can 
also be an alternative to meeting patients’ calorie 
requirements.1 Besides having advantages in terms 
of lower cost and reduced risk of infection, 
administration of at least 20% of nutrients through 
enteral nutrition can help maintain intestinal flora, 
reduce bacterial translocation, and maintain mucosal 
integrity and immune function.10  
ECF patients with high output (>500 mL/day), 
experiencing intestinal obstruction, ECF drainage 
that significantly worsens wound conditions and 
skincare or interferes with the ability to maintain 
fluid and electrolyte balance when EN is used, 
require parenteral nutrition (PN ) to meet nutritional 
needs to support spontaneous or surgical ECF 
closure.11 Some contraindications to PN 
administration are impaired liver function, difficulty 
in vascular access, or infection in the vicinity of the 
vascular access location. In general, PN is required 
in most high-output ECF patients, although it is only 
in the early phase, and it has been used to reduce 
ECF output secretion by 30% to 50% and contribute 
to ECF closure.12 The flow path of selecting 
nutritional pathways for ECF patients is provided in 
Figure 2. 
An oral route can be chosen for ECF patients with 
high output, with the following modifications: i) 
limiting low sodium fluid intake to 500mL/day, ii) 
providing patients with high sodium oral solution 
(90-120 mmol/L sodium level), iii) giving nutrition 
in forms of solid food and fluid in a small amount, 
and iv) providing combined administration of proton 
pump inhibitors, antimotility drugs, and 
octreotide.13 Home Parenteral Nutrition (HPN) is 
recommended when patients are medically stable 
and fistula output can be managed. The example can 
be taken from patients awaiting surgeries.11  
Fistuloclysis is defined as "a technique using 
fistulas as the main enteral pathway for access and 
entry of food ingredients, formulas, or 
gastrointestinal secretions”. Fistulas are a low-cost 
method compared to the use of standard polymer 
nutrients instead of PN, but are rarely performed 
because of technical, anesthetic, and patient comfort 
issues. Fistuloclysis technique requires the presence 
of experienced medical personnel for the installation 
in order for the food hose to remain stable, unleaked, 
and unattracted by peristalsis. Leakage of 
fistuloclysis will cause skin corrosion, thus allowing 
for infection. Fistuloclysis can stimulate fistula 
epithelialization, so it can reduce the possibility of 
spontaneous closure of fistulas.12 Therefore, 
fistuloclysis is only recommended in fistulas which 
are predicted not to close spontaneously. In the 
administration of initial fistuloclysis, it is 
recommended to use a polymer formula, which can 
be converted into an oligomeric diet if intolerance 
occurs.11  
The volume of ECF output also needs to be taken 
into consideration. Generally, fistuloclysis can be 
used an option in ECF cases when the location is 
proximal to ensure that nutrition can still be 
absorbed sufficiently or when TPN administration is 
not applicable or contraindicated. As stated by 
Coetzee et al.14, re-administration of chyme through 
fistuloclysis does not cause side effects and can be 
considered to increase enteral feeding tolerance and 
maintain fluid and electrolyte homeostasis. 
Although fistuloclysis is normally carried out in 
low-output ECF, Niu et al. 15 stated that in high-
output ECF cases (in 1500-2000 mL/day), 
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nutritional administration through fistuloclysis can 
be conducted by percutaneous enterostomy over a 





Energy requirements should be assessed for patients 
with ECF. In this regard, the most accurate method 
for calculating energy requirements is by using 
indirect calorimetry. If indirect calorimetry is not 
applicable, the Harris-Benedict equation can be used 
to calculate nutrient requirements. ECF patients 
typically have catabolic and hyper-metabolic 
conditions. Basal energy requirements can be 
estimated using the Harris-Benedict equation with a 
modification of 1 to 2.5 times from basal energy 
requirements of healthy adults, depending on the 
amount of output.1 According to the ESPEN 
recommendation, the guidelines outlined in the 
Rules of Thumb can also be applied to ECF patients 
who have complications of intestinal failure, i.e., 
energy requirements of 25-35 kcal/kg/day, 
depending on  patients’ clinical conditions.19 
In obese patients with ECF, nutrition can be given 
to critical patients according to the guidelines set by 
ASPEN and Society of Critical Care Medicine 
(SCCM). For instance, requirements vary from 11 to 
14 kcal/kg of body weight per day if BMI is in the 
range of 30-50kg/ m2; and requirements range from 
22 to 25 kcal/kg of body weight per day if BMI is 




In patients with ECF, the amount of protein loss 
through enteric secretion can reach 75 grams a day.1 
The provision of protein in ECF patients is based on 
the amount of output produced by enteric secretion. 
However, it can be given 1.5-2.0 g/kg/day in 
general. In patients with entero-atmospheric fistulas 
and high-output ECF, protein administration can 
stand at 2.5 g/kg/day.11 In obese patients with ECF, 
protein administration of 2g/kg of body weight per 
day is recommended for patients with BMI at a 
range of 30-40kg/m2; and protein administration of 
2.5 g/kg of body weight per day for those with BMI 
of >40 kg/m2.20 To date, there are no specific 
recommendations regarding carbohydrate and fat 




Vitamins and minerals are wasted because of either 
enteric fluid secreted by ECF patients or impaired 
absorption associated with gastrointestinal 
dysfunction. As a result, deficiencies for these types 
of micronutrients can be predicted by examining the 
anatomical digestive dysfunction that occurs in 
patients. Fistulas that take place in the proximal 
jejunum, for example, are likely to make them suffer 
from deficiencies of fat-soluble vitamins and water-
soluble vitamins. However, if fistulas are situated in 
the ileum, particularly before 50-60 cm of terminal 
ileum, they will have deficiencies of vitamin B12 
and fat-soluble vitamins. In this case, vitamin B12 
needs to be injected. Besides, patients will get 
exposed to suffering from zinc and vitamin C 
deficiencies. With high-output ECF, patients will 
also be prone to have magnesium deficiency. 
Consequently, administration of intravenous 
magnesium sulfate or oral magnesium chloride can 
be given to increase enteral absorption.2 In relation 
to this, it is suggested to administer twice the 
standard requirements for vitamins and minerals and 
five to ten times the standard requirements for zinc 




As regards with specific nutrients, there is no certain 
advice on the use of immunonutrient formulas due 
to inadequate evidence. However, oral glutamine 
supplementation has been used to reduce the rate of 
mortality and increase the closure of fistulas. 
Glutamine, apart from being the main nutrient of 
intestinal cells, plays an important role in the 
immune system by increasing secretory IgA 
production in the intestinal mucosa.11 As said by de 
Aguilar-Nascimento, et al.8, fistula resolution is 13 
times greater in patients receiving oral glutamine of 
0.3 g/kg/day in addition to PN (OR = 13.2 (95% CI 
= 1,1-160.5); p=0.04). Nevertheless, glutamine 
metabolism will not be optimal in individuals with 
kidney, liver, or sepsis failure, since they have a 
higher risk of toxicity.11 According to a study by 
Martinez et al.21, enteral administration of 4.5 g of 
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arginine and 10 g of glutamine in a preoperative 
ECF patient for seven days can reduce the 
recurrence risk and the inflammatory cytokines for 
one week postoperatively. Other immunonutrient 
supplements such as arginine, omega-3 fatty acids, 
and nucleotides have yet to be proven in ECF 
cases.16 Omega-3 is regularly indicated in critically 
ill patients, yet the current evidence gives rise to  
controversy.22–24 
 
4. Providing patients with pharmacotherapy 
 
In adult patients with high-output ECF, 
administration of somatostatin and somatostatin 
analogs is recommended as a method to reduce 
effluent drainage and increase spontaneous closure. 
In relation to somatostatin, it has a very short half-
life of 1-2 minutes and is naturally produced in the 
pancreas of the digestive tract. Besides, octreotide is 
an example of somatostatin analogs and has a much 
longer half-life of 113 minutes. Somatostatin and 
somatostatin analogs can inhibit the release and 
secretion effects of varying gastrointestinal 
hormones and increase the absorption of water and 
electrolytes, thus extending the intestinal transit time 
and, eventually, reducing the volume of 
gastrointestinal secretions.11 
Despite the support of varied meta-analyses25–27 
to the effectiveness of using somatostatin and 
somatostatin analogs in increasing the likelihood of 
spontaneous closure, de Vries, et al.28 mentioned 
that somatostatin and its analogs are not conclusive 
in their benefits for reducing fistula output. In the 
study, three classes of drugs, namely proton pump 
inhibitors, antimotility agents (loperamide), and 
histamine receptor antagonists, can reduce fistula 
output effectively with a confidence level of 2b. 
 
5. Carrying out monitoring and evaluation 
 
Some of the benchmarks for successful nutritional 
management in ECF cases include achieving an 
anabolic state, which is regularly signaled by weight 
gain and increased levels of albumin, prealbumin, 
and transferrin, and meeting the needs of 
micronutrients for optimal healing.1 Albumin, 
prealbumin, and transferrin themselves are acute-
phase proteins whose levels are not accurate under 
conditions of acute stress and sepsis. Serum albumin 
is the most common plasma protein, representing 
about 50% of the total protein content (3.5-5 g/L). 
Albumin production in the liver is regulated by 
osmolarity and oncotic pressures. It is stimulated by 
hormonal factors (insulin, cortisol, and growth 
hormone) and is inhibited by acute-phase cytokines, 
such as interleukin (IL) -6 and tumor necrosis factor 
(TNF)-α. Futhermore, prealbumin and albumin 
levels provide an indirect assessment of visceral 
protein storage, while transferrin is the main iron 
transport protein in plasma. Albumin and transferrin 
levels have been used to predict the rates of 
spontaneous closure and mortality.1 Spontaneous 
fistula closure is 18.1-fold greater in ECF cases with 
improvement in serum albumin compared to those 
without repair.8 Prealbumin levels can function as an 
indicator of nutrition, followng that they can 
describe the adequacy of protein due to a very short 
half-life.18,2 The use of the c-reactive protein (CRP) 
test is not specific in ECF cases, but can be used in 
conjunction with prealbumin. The ratio of CRP to 
prealbumin has been validated to be prognostic to 
spontaneous closure of fistulas. For patients with a 
ratio of less than or equal to 0.2, fistula closure 
occurs in 87.0% (95% CI, 74.0-94.3), whereas for 
patients with a ratio of greater than 1.0, no fistulas 
are closed.17 
Anthropometry evaluation in ECF cases is given 
to body weight, body mass index (BMI), mid-upper 
arm circumference (MUAC), and thick skin folds. 
The measurement of MUAC can provide a more 
accurate estimate in patients with edema. For 
patients with unstable fistula output, there is a high 
risk of dehydration, causing the results of weight 
measurements to become biased. The same 
condition arises for bioelectrical impedance analysis 
(BIA). This examination will only be accurate in 
individuals with stable fluid balance because it is 
influenced by body cell mass, integrity, and function 
of cell membranes.11 Nonetheless, anthropometric 
and biochemical tests (electrolytes, hemoglobin, 
CRP, IL-6, albumin) are still recommended to 
monitor the risk of dehydration and malnutrition. 
Intake tolerance needs to be evaluated to assess 
the provided nutritional therapy and supplemental 
nutrition. The clinical symptoms of refeeding 
syndrome also have to be evaluated in patients, 
especially those with malnutrition. In this regard, 
malnutrition screening needs to be done regularly to 
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identify the presence of malnutrition as early as 
possible, as given in Chapter 2.2.11 Patients 
receiving enteral nutrition through either duodenum 
or jejunum are at risk for developing dumping 
syndrome’s symptoms. 
When patients receive EN, their tolerance to EN 
and ability to achieve the target intake must be 
assessed daily.11 The lipid profile can be examined 
from ECF patients, especially those receiving PN. 
Increased triglyceride levels are frequently found in 
ECF cases, which can lead to dysregulated immune 
system, heart and lung functions, and increased liver 
steatosis. As stated by Visschers et al.29, sepsis, PN, 
high-output small intestinal fistula, and 
inflammatory bowel disease are independent risk 
factors for hypertriglyceridemia. In clinical 
practices, triacylglycerol containing long-chain fatty 
acids (LCFA) is a major component of PN in PN 
lipids. The transport of LCFA depends on the carrier 
protein in the cell membrane, which is responsible 
for transporting fatty acids into cells and 
mitochondria to undergo oxidation. Increased levels 
of LCFA that are beyond the amount of carrier 
protein will result in accumulation, manifested by 
liver steatosis. 
Nitrogen balance has a clinical significance, 
which indicates patients' anabolic status.1 It can be 
calculated by assessing the amount of nitrogen 
intake and nitrogen output. To do this, urine needs 
to be stored for 24 hours to calculate the urine urea 
nitrogen level. Nitrogen balance will be meaningful 
only if patients experience sepsis resolution. If the 
value is negative, this indicates that the nutritional 
therapy given needs to be evaluated and modified. 
In ECF cases, a correction factor in the calculation 
of nitrogen balance due to protein loss through 
fistula output must be considered with additional 1g 
of nitrogen output for every 500 ml of fistula 
output.30 The modified nitrogen balance equation in 
ECF patients applies as follows: Nitrogen balance = 
[Protein intake (g) ÷ 6,25] - urine urea nitrogen 
(NUU) + 4 g + (2 g × amount of enteric fluid loss in 
liters)].12 
Citrulline, a non-essential amino acid produced 
by enterocyte cells, has high sensitivity and 
specificity to predict permanent bowel failure when 
the serum level is below 20 mol/L. Citrulline is also 
an alternative biomarker to assess the intestinal 
length that is functional for absorption.18 
If fistulas do not close spontaneously within 30 to 
40 days or they cannot close due to various 
comorbidities, surgery should be considered 
immediately by maintaining the nutritional support. 
Aside from this, an acronym is commonly used to 
remember the factors that complicate spontaneous 
closure, namely "FRIEND". This acronym stands 
for F - Foreign body; R - Radiation; I - Inflammation 
or infection; E - Epithelialization of the fistula tract, 
N - Neoplasm; and D - Distal obstruction.31 
Based on the location, spontaneous closure is more 
likely to occur in upper gastrointestinal fistulas 
(proximal to the duodenojejunal flexure). Fistulas 
located in the upper gastrointestinal tract are 
generally side fistulas without any residual disease 
of the gastrointestinal tract. These fistulas differ 
from lower gastrointestinal fistulas that are 
commonly associated with Crohn's disease, 
radiation enteritis, or ischemia. Although the rates of 
spontaneous closure vary considerably between 
upper and lower gastrointestinal fistulas, their rates 




Enterocutaneous fistula (ECF) management requires 
a multidisciplinary team as an approach to achieve 
an optimal clinical output. The purpose of nutritional 
medical therapy in ECF cases is to adequately 
estimate nutritional needs, maintain fluid and 
electrolyte balance, and stimulate spontaneous ECF 
closure whenever possible. To achieve an optimal 
outcome, an analysis of nutrition needs has to be 
conducted individually by considering the etiology, 
the anatomical fistula location, and the amount of 
output. This appears to be so important that the 
selection of nutritional pathways, the regulation of 
macronutrient and micronutrient requirements, the 
use of specific nutrients, and the provision of 
pharmacotherapy can be made with the right 
indications. 
It is preferred that EN therapy is provided in ECF 
cases with low output, proximal location, and no 
distal obstruction. However, combined nutrition 
therapy of EN and PN can be initiated if the intake 
cannot be toleranced. Energy requirements should 
be measured by using indirect calorimetry. If 
indirect calorimetry is not applicable, it can be 
altered to other standard equations such as the 
 
World.Nutr.Journal | 12  
Harris-Benedict or the Rules of Thumb. As regards 
with the provision of protein, it is given 1.5-2 
g/kg/day based on patients’ clinical considerations. 
Micronutrient supplementation may be needed in 
cases of high-output fistulas. Glutamine and specific 
nutrients can increase the likelihood of spontaneous 
closure of fistulas and are associated with a better 
postoperative output. For instance, 
pharmacotherapy, somatostatin, and its analogs are 
recommended in high-output ECF cases.  
In addition, evaluation and monitoring have to be 
carried out regularly in order to identify 
complications, particularly for sepsis, dehydration, 
and malnutrition. Anthropometric assessments to 
daily body weight, fluid balance, nitrogen balance, 
vital signs, and biochemistry (prealbumin, CRP, 
lactate, lipid profile, organ function, and 
electrolytes), also function as essential indicators to 














Figure 1. Proposed algorithm of nutrition management in 
enterocutaneous fistula. 
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